Disruptive Technology Channel Cancer Detection Meets Portfolio Perfection: The ARKG ETF By Tom LydonApril 13, 2021
Disruptive Technology Channel The ARKG ETF: Genomics Exposure with a Twist By Tom LydonApril 12, 2021
Disruptive Technology Channel How ARKG’s Genomics Will Personalize Cancer Treatment By Tom LydonMarch 31, 2021
Disruptive Technology Channel Synthetic Biology: What It Is and Why ‘ARKG’ Is So Levered to It By Tom LydonMarch 16, 2021
Featured ETFGI Reaches New ETF Record of $5.52 Trillion In Invested Assets By Aaron NeuwirthFebruary 16, 2021
Disruptive Technology Channel Liquid Biopsies? Just Another Day in the Life for ‘ARKG’ By Tom LydonFebruary 12, 2021
Smart Beta Channel Today’s OverARKing Theme? 5 Active ETFs from Ark Invest By Ben HernandezFebruary 11, 2021
Disruptive Technology Channel Cancer Screening? There’s an ARK ETF for That By Tom LydonFebruary 9, 2021
Disruptive Technology Channel Unlock the Long-Term Genomics Runway with ‘ARKG’ By Tom LydonFebruary 3, 2021
Disruptive Technology Channel Long Read Sequencing Is Here. The ARKG ETDF Is Ready By Tom LydonJanuary 29, 2021
Disruptive Technology Channel Targeted ETF Strategies to Capture Technological Breakthroughs By Max ChenJanuary 27, 2021
Disruptive Technology Channel An ‘Omics Revolution: What’s Next for High-Flying ‘ARKG’ By Tom LydonJanuary 26, 2021
Disruptive Technology Channel Big Ideas 2021: Technological Breakthroughs Investors Shouldn’t Miss By Max ChenJanuary 25, 2021
Disruptive Technology Channel ARKG: Access the Latest and Greatest Genomics Innovation By Tom LydonJanuary 21, 2021
Disruptive Technology Channel The ARKG ETF: Join the Genomics Revolution By Tom LydonJanuary 19, 2021
Disruptive Technology Channel Cancer Detection & Investing Selection: The ARKG ETF By Tom LydonJanuary 8, 2021
Featured Moderna Helps Biotech ETFs Mitigate Massive Losses as Stocks Tumble By Ian YoungJanuary 4, 2021
Disruptive Technology Channel Disruption Lurks in 2021. ARKK and ARKG Are Ready For It By Tom LydonDecember 30, 2020